SML3671

Brivanib

≥98% (HPLC)

• Synonym(e): (2R)-1-[4-[(4-Fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxypropan-2-ol, (2R)-1-[[4-[(4-Fluoro-2-methyl-1H-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxy]-2-propanol, (R)-1-(4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-ol, BMS 540215, BMS 582664 active drug, BMS-540215, BMS-582664 active drug, BMS540215, BMS582664 active drug
• Empirische Formel (Hill-System): C₁₉H₁₉FN₄O₃
• CAS-Nummer: 649735-46-6
• Molekulargewicht: 370.38
• UNSPSC Code: 12352200
• NACRES: NA.25
• MDL number: MFCD13194684
• Assay: ≥98% (HPLC)
• Form: powder

Eigenschaften

• Quality Segment: 100
• assay: ≥98% (HPLC)
• form: powder
• color: white to beige
• solubility: DMSO: 2 mg/mL, clear
• storage temp.: -10 to -25°C
• SMILES string: Fc1c2c([nH]c(c2)C)ccc1Oc3ncn[n]4c3c(c(c4)OC[C@H](O)C)C
• InChI: 1S/C19H19FN4O3/c1-10-6-13-14(23-10)4-5-15(17(13)20)27-19-18-12(3)16(26-8-11(2)25)7-24(18)22-9-21-19/h4-7,9,11,23,25H,8H2,1-3H3/t11-/m1/s1
• InChI key: WCWUXEGQKLTGDX-LLVKDONJSA-N

Beschreibung

Biochem/physiol Actions

Brivanib (BMS-540215) is an orally active, ATP-competitive FGF & VEGF receptor tyrosine kinase inhibitor (VEGFR-1/2/3 IC50 = 380/25/10 nM; FGFR-1/2/3 IC50 = 148/125/68 nM). Brivanib inhibits VEGF-stimulated and basic FGF-stimulated proliferation in endothelial cultures (IC50 = 40 & 276 nM, respectively) and displays antitumor efficacy in vivo (30-90 mg/kg via daily p.o. in mice with H3396 xenografts).

Orally active, ATP-competitive FGF & VEGF receptor tyrosine kinase inhibitor with antitumor efficacy in vivo.

Sicherheitshinweise

• Lagerklasse: 11 - Combustible Solids
• Was ist los?: WGK 3
• Flammpunkt (°F): Not applicable
• Flammpunkt (°C): Not applicable